Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials.
- DOI
- 10.1136/rmdopen-2025-006624
- Published
- 2026 Jul 3
- Container
- RMD open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/rmdopen-2025-006624,
title = {Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials.},
author = {Parodis I and Lindblom J and Levy RA and Tsoi A and Zen M and Nikolopoulos D and Khamashta M and Tomlinson R and Askanase A and van Vollenhoven R and Nikpour M},
year = {2026},
journal = {RMD open},
doi = {10.1136/rmdopen-2025-006624},
url = {https://doi.org/10.1136/rmdopen-2025-006624}
}RIS
TY - JOUR TI - Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials. AU - Parodis I AU - Lindblom J AU - Levy RA AU - Tsoi A AU - Zen M AU - Nikolopoulos D AU - Khamashta M AU - Tomlinson R AU - Askanase A AU - van Vollenhoven R AU - Nikpour M PY - 2026 JO - RMD open DO - 10.1136/rmdopen-2025-006624 UR - https://doi.org/10.1136/rmdopen-2025-006624 ER -
APA
I, P., J, L., RA, L., A, T., M, Z., D, N., M, K., R, T., A, A., R, V. V., & M, N. (2026). Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials.. RMD open. https://doi.org/10.1136/rmdopen-2025-006624
Source records
- pubmed · retrieved 2026-11-11T03:53:21.237Z